Skip Navigation

Annals of Oncology 2007 18(Supplement 10):x1-x2; doi:10.1093/annonc/mdm407
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by George, D
Right arrow Articles by Verweij, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by George, D
Right arrow Articles by Verweij, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

symposium articles

Introduction to ‘A multitargeted approach: clinical advances in the treatment of solid tumours’

D George1,* and J Verweij2

1 Division of Urology, Duke University Medical Center, Durham, NC, USA
2 Erasmus University Medical Centre, Rotterdam, The Netherlands

* Correspondence to: Dr Daniel George, Associate Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology, Duke University Medical Center, Durham, NC 27705, USA. Tel: +919-668-8108 (+ #3); Fax: +919-668-7117; E-mail: Daniel.george{at}duke.edu

Although single-target agents have been shown to improve patient outcomes in certain tumour types, drug resistance often occurs due to salvage pathways that compensate for the inhibited signalling pathway. Simultaneous inhibition of individual target receptors along multiple pathways has been shown to have additive inhibitory effects on tumour growth and vasculature, and data supporting the efficacy of strategies incorporating multitargeted agents in the treatment of several tumour types have already begun to emerge in the clinical setting. This supplement provides an overview of presentations from a satellite symposium that took place at the European Society of Medical Oncology congress on 29 September 2006, entitled ‘A Multitargeted Approach: Clinical Advances in the Treatment of Solid Tumours’, which discusses the most recent data on multitargeted agents with a focus on sunitinib malate (Sutent®, Pfizer Inc.).

Key words: sunitinib, TKI, angiogenesis, VEGF, multitargeted


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.